On CNBC's “Halftime Report Final Trades,” Kevin Simpson of Capital Wealth Planning said The TJX Companies, Inc. TJX is a ...

AbbVie and Genmab co-commercialize the blood cancer drug Epkinly in the U.S. and Japan. However, Genmab established itself as a potential direct competitor to AbbVie in other areas when it bought ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

The document says that AbbVie booked 99% of its 2020 prescription ... including Abbott Laboratories, Merck & Co and reportedly also Bristol-Myers Squibb. Its publication comes amid plans by ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its expectations for annual sales growth in the high single-digit percentage ...

AbbVie Inc. (NYSE: ABBV ... Currently Novo Nordisk A/S (NYSE: NVO) with Ozempic and Eli Lilly and Co. (NYSE: LLY) with Zepbound are the major players. And like those two drugs, GUB014295 (also ...

As Friday approaches, investors are eagerly anticipating reports from industry giants AbbVie, Exxon Mobil (NYSE ... $731.15M • Piper Jaffray Co (PIPR) - EPS: $3.93, Revenue: $454.61M • Gentex ...

Yochi Slonim, co-founder and CEO of Anima, said: “We are excited to partner with AbbVie, a recognised global leader in oncology and immunology, and are looking forward to start working with ...

The stock is down over 95% YTD. AbbVie Inc. (700% Jump in Message Volume) Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...